Skip to main content
. Author manuscript; available in PMC: 2009 Mar 10.
Published in final edited form as: Chem Biol Interact. 2007 Nov 22;172(1):81–92. doi: 10.1016/j.cbi.2007.11.005

Figure 1.

Figure 1

Transformation and immortalization of EBV-infected B lymphocytes treated with DMDTC. Human Ficoll-purified PBMC (A) or isolated B lymphocytes (B) were infected with B95-8 EBV supernatants, treated with DMDTC or buffer, cultured for 4 weeks and colonies enumerated. Cells from resulting colonies were then subcultured under limiting dilution conditions for another 4 weeks and cloning efficiency expressed as the percent of immortalized colonies (%) for PBMC (C) or purified B lymphocytes (D). Results represent the average number of colonies per treatment group from triplicate cultures +/− SEM. Asterisks indicate significant difference from buffer-treated cultures using Student t-test (p ≤ 0.05). Data is representative of 1 out of 6 independent experiments performed using PBMC, and 1 out of 8 independent experiments using isolated B lymphocytes. Cells for each experiment were obtained from different donors (n=14).